Signed Endorsement Letters for the Updated List of Vat-Exempt Medicines Under Republic Act 11534 known as Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act

The Food and Drug Administration (FDA) endorses to the Bureau of Internal Revenue (BIR) the updated list of VAT-Exempt Medicines (as of March 2022) under RA 11354, otherwise known as the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.

Check the signed endorsement letter dated 04 March 2022 to see the additional medicines for inclusion in the VAT-exempt list.

Signed BIR VAT Exempt Endorsement Letter as of March 04, 2022

FDA likewise informed the BIR of the corrections in the specifications of some of the medicines included in the VAT-Exempt list through their letter dated 10 March 2022. Please refer to the signed endorsement letter for more information.

Signed BIR VAT Exempt Endorsement Letter as of March 10, 2022